Trials
2 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.”In the company’s words, NCT05848739 on ClinicalTrials.gov
- Given with
- Lonsurf (Taiho Oncology)Other companies’ drugs in its trials
Other drugs for Colon Cancer
- DostarlimabGSK · Phase 3
- NuvastaticNatureceuticals Sdn Bhd · Phase 3
- XLJDOD compound granuleJiangsu Famous Medical Technology Co., Ltd. · Phase 3
- RC148RemeGen · AbbVie · Phase 2/3
- INCA33890Incyte Corporation · Phase 3
- CalderasibMerck & Co. · Phase 3
Coming up2
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 31 Dec 2026 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | |
| Phase 1Not yet recruiting | 31 Dec 2028 | A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026